Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacific Biosciences sees strong Revio demand driving revenue growth

PACB reported a revenue decrease in Q4 2022 but saw strong customer interest in the Revio system, driving revenue growth expectations for 2023. The company is strategically focused on Revio adoption, Onso's performance, and managing market challenges. Opportunities exist in scaling manufacturing capacity, expanding customer reach, and leveraging high demand for Revio and Onso.

PacBio surpasses revenue expectations with strong Revio demand

PacBio's Q1 2023 performance exceeded expectations with record revenue and strong Revio demand, setting up growth opportunities.
While facing challenges in gross margin and operating expenses, PacBio's innovative approach and broad market appeal position it well for the future.
With a focus on margin expansion, consumables growth, and balancing product demand, PacBio aims for sustained profitability and market leadership.
The successful Revio launch and strong China business highlight PacBio's potential for long-term growth and market impact.

PacBio reports record Q2 revenue, eyes market gains and gross margin improvements

PacBio's Q2 performance marked by record revenue, strategic acquisitions, and strong guidance update for 2023 growth.
Focus on Revio system adoption, consumables pull-through, and backlog reduction positions the company for sustained success.
Challenges include market competition, sustaining growth post-upgrade cycle, and addressing validation issues for new products.
Opportunities lie in market shifts towards long reads, improving gross margins through product mix changes, and expanding market access.

PacBio reports record Q3 revenue growth and strategic advancements

PacBio delivered robust performance in Q3, achieving record revenue and strong growth, driven by increased demand for Revio systems and consumables.
While facing challenges such as budget constraints and macroeconomic uncertainties, PacBio's strategic strengths lie in product innovation, market expansion, and financial stability.
Opportunities abound in collaborations, technology enhancements, and market growth, positioning PacBio for continued success and leadership in the genomics industry.
With a positive outlook for future revenue growth, PacBio remains focused on driving innovation, expanding its customer base, and navigating market challenges.

Pacific Biosciences reports robust 2023 performance and eyes growth

PACB had a strong 2023 with revenue growth and successful Revio adoption, despite challenges in China impacting placements.
New kits, software updates, and positive customer feedback on platforms indicate market acceptance and drive customer enthusiasm.
Strategic priorities for 2024 focus on expansion, technology development, and revenue growth, with opportunities in clinical markets and alternative business models.

Pacific Biosciences reports Q2 revenue below expectations, focuses on growth

Pacific Biosciences of California reported Q2 revenue below expectations but showed strength in consumable revenue growth. The company is focused on reducing expenses, improving cash burn, and driving instrument placements. Despite challenges, there are opportunities for growth through attractive deals and positive outlook for consumables.
The company's performance in Q2 reflects ongoing efforts to improve margins and drive revenue growth. Challenges in revenue expectations and headwinds are being addressed through cost reductions and strategic initiatives. Pacific Biosciences remains confident in its progress and future prospects.
With a focus on cost reduction, revenue improvement, and strategic priorities, Pacific Biosciences aims to achieve cash flow positivity by 2026. The company's strengths lie in consumable revenue growth, successful marketing events, and confidence in its product pipeline. Challenges in revenue and cash flow are being managed with opportunities for growth through instrument placements and deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK, Calif. , March 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023.

PacBio To Begin Commercial Shipment of Revio Systems

MENLO PARK, Calif. , Feb. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts.

PacBio to Present at Cowen's 43rd Annual Health Care Conference

Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.

PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Todd Friedman - Director, Investor Relations Christian Henry - President & Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Julia Qin - JPMorgan Tejas Savant - Morgan Stanley Dan Brennan - Cowen David Westenberg - Piper Sandler Sung Ji Nam - Scotiabank John Sourbeer - UBS Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the PacBio Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc. (PACB) Q4 2022 Earnings Call Transcript

MENLO PARK, Calif. , Feb. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2022.

PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Fintel reports that Jackson Square Partners has filed a 13G/A form with the SEC disclosing ownership of 15.01MM shares of Pacific Biosciences of California Inc (PACB).

Jackson Square Partners Cuts Stake in Pacific Biosciences of California

Bionano Genomics

Sangamo Therapeutics

These cutting-edge biotech companies quickly fell out of favor with investors this week.

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems MENLO PARK, Calif. , Feb. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of a program intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and Revio™ sequencing systems.

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Illumina

The gene sequencing market is ripe for disruption. ILMN suffers from multiple strategic setbacks that will likely impact margins for years.

Illumina, Pacific Biosciences, And Oxford Nanopore Market Position Comparison

MENLO PARK, Calif. , Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.

PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock

MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering.

Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock

ARK Innovation ETF

Coinbase

CRISPR Therapeutics

DraftKings

Exact Sciences

Invitae

Roblox

Roku

10X Genomics

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022.

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.

PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales

Pacific Biosciences of California (PacBio) PACB shares are trading higher today after the company announced it received orders for 76 Revio systems in the fourth quarter of 2022. The company also issued preliminary fourth-quarter revenue results.

Why Pacific Biosciences Of California Shares Are Trading Higher Today - Pacific Biosciences (NASDAQ:PACB)

PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history.

PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022

MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo, Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.

PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration

MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P.

PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference

PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the company's long-read technology, and can unlock revenue growth and gross margins improvements.

Pacific Biosciences: New Products Set To Drive Strong Growth And Margin Improvement

Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the Children's Rare Disease Cohorts Initiative (CRDC) at Boston Children's Hospital.

PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing

PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.

PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Todd Friedman - Director of Investor Relations Christian Henry - President & Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Julia Qin - JPMorgan Dan Brennan - Cowen Kyle Mikson - Canaccord Operator Hello, and welcome to the PacBio Third Quarter Fiscal Year 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc. (PACB) Q3 2022 Earnings Call Transcript

MENLO PARK, Calif. , Nov. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022.

PacBio Announces Third Quarter 2022 Financial Results

World Class Team Will Provide Strategic Guidance and Direction for PacBio's Research and Development Activities MENLO PARK, Calif. , Nov. 2, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it is bringing together a group of scientific experts to form PacBio's Scientific Advisory Board (SAB).

News for Pacific Biosciences of California Stock (PACB)